Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.34 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626243 | 0.87 | DGAT1 (0.44) | LMNADGAT1DYRK1AIDO1CYP19A1 | |
| SCHEMBL19629501 | 0.87 | LMNA (0.41) | LMNADYRK1AIDO1CYP19A1ABCC2 | |
| SCHEMBL16608608 | 0.84 | DGAT1 (0.41) | DGAT1CA12CA9 | |
| SCHEMBL19626262 | 0.81 | DYRK1A (0.38) | LMNADGAT1DYRK1ACYP19A1ABCC2 | |
| SCHEMBL19626289 | 0.80 | CHUK (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL19629504 | 0.74 | LMNA (0.37) | LMNADGAT1DYRK1AIDO1CYP19A1 | |
| SCHEMBL16608665 | 0.74 | CHUK (0.59) | — | |
| SCHEMBL16608396 | 0.73 | DGAT1 (0.38) | DGAT1CA12CA2CA9 | |
| SCHEMBL19626258 | 0.73 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL4312796 | 0.73 | DGAT1 (0.43) | LMNADGAT1DYRK1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | LMNA 2591/4885DGAT1 2063/4885DYRK1A 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.